[go: up one dir, main page]

BR0204470A - Uso de flavivirus para a expressão de epitopos de proteìna e para o desenvolvimento de um novo virus vacinal vivo atenuado para imunização contra flavivirus e outros agentes infecciosos - Google Patents

Uso de flavivirus para a expressão de epitopos de proteìna e para o desenvolvimento de um novo virus vacinal vivo atenuado para imunização contra flavivirus e outros agentes infecciosos

Info

Publication number
BR0204470A
BR0204470A BR0204470-6A BR0204470A BR0204470A BR 0204470 A BR0204470 A BR 0204470A BR 0204470 A BR0204470 A BR 0204470A BR 0204470 A BR0204470 A BR 0204470A
Authority
BR
Brazil
Prior art keywords
flaviviruses
expression
development
protein epitopes
infectious agents
Prior art date
Application number
BR0204470-6A
Other languages
English (en)
Inventor
Mirna C Bonaldo
Ricardo Galler
Marcos Da Silva Freire
Richard C Garrat
Original Assignee
Fundacao Oswaldo Cruz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacao Oswaldo Cruz filed Critical Fundacao Oswaldo Cruz
Publication of BR0204470A publication Critical patent/BR0204470A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"USO DE FLAVIVIRUS PARA A EXPRESSãO DE EPITOPOS DE PROTEìNA E PARA O DESENVOLVIMENTO DE UM NOVO VIRUS VACINAL VIVO ATENUADO PARA IMUNIZAçãO CONTRA FLAVIVIRUS E OUTROS AGENTES INFECCIOSOS". A presente invenção se refere a uma vacina contra infecções causadas por flavivirus. Mais particularmente, se refere ao uso do vírus vacinal YF (17D) para expressar ao nível de seu envelope, epitopos de proteína a partir de outros patógenos que induzião uma resposta imuno específica ao patógeno parental.
BR0204470-6A 2001-03-09 2002-03-08 Uso de flavivirus para a expressão de epitopos de proteìna e para o desenvolvimento de um novo virus vacinal vivo atenuado para imunização contra flavivirus e outros agentes infecciosos BR0204470A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0105877A GB2372991B (en) 2001-03-09 2001-03-09 Flavivirus expression vector
PCT/BR2002/000036 WO2002072835A1 (en) 2001-03-09 2002-03-08 Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents

Publications (1)

Publication Number Publication Date
BR0204470A true BR0204470A (pt) 2004-09-08

Family

ID=9910352

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0204470-6A BR0204470A (pt) 2001-03-09 2002-03-08 Uso de flavivirus para a expressão de epitopos de proteìna e para o desenvolvimento de um novo virus vacinal vivo atenuado para imunização contra flavivirus e outros agentes infecciosos

Country Status (10)

Country Link
US (2) US20030194801A1 (pt)
EP (1) EP1366170A1 (pt)
AP (1) AP2002002685A0 (pt)
AU (1) AU2002235678B2 (pt)
BR (1) BR0204470A (pt)
CA (1) CA2408214A1 (pt)
GB (1) GB2372991B (pt)
OA (1) OA12287A (pt)
WO (1) WO2002072835A1 (pt)
ZA (1) ZA200209371B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
BR0210907A (pt) 2001-06-01 2004-12-21 Acambis Inc Vetores de flavivìrus quiméricos
AU2003267937C1 (en) * 2002-01-15 2019-08-08 Sanofi Pasteur Biologics, Llc Flavivirus vaccines
US20050002968A1 (en) * 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
WO2003101397A2 (en) * 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines
KR100710519B1 (ko) * 2002-10-09 2007-04-24 (주)씨아이디 일본뇌염 바이러스의 신규한 전체-길이의 게놈 ＲＮＡ 및상기 ＪＥＶ 게놈 ＲＮＡ에 대한 감염성이 있는 ＪＥＶｃＤＮＡ 및 이것의 용도
DK1558276T3 (da) 2002-11-08 2012-10-22 Univ Tulane Flavivirus-fusionsinhibitorer
JP4683926B2 (ja) * 2002-11-15 2011-05-18 サノフィ パスツール バイオロジクス カンパニー ウエストナイルウイルス・ワクチン
WO2005040390A1 (en) * 2003-07-21 2005-05-06 Shanghai Tengen Biomedical Co., Ltd. A recombinant vaccine using yellow fever virus as vector
RU2009105099A (ru) * 2006-07-14 2010-08-27 Санофи Пастер Байолоджикс Ко. (Us) Конструирование рекомбинантных вирусных вакцин путем прямой транспозон-опосредованной инсерции чужеродных иммунологических детерминант в белки векторного вируса
AR063606A1 (es) 2006-11-07 2009-02-04 Acambis Inc Estabilizacion de vacunas mediante liofilizacion
US20080294361A1 (en) * 2007-05-24 2008-11-27 Popp Shane M Intelligent execution system for the monitoring and execution of vaccine manufacturing
WO2009024534A2 (en) * 2007-08-17 2009-02-26 Intercell Ag Japanese encephalitis virus (jev) and tick-borne encephalitis virus (tbev) peptides stimulating human t cell responses
JP5689687B2 (ja) 2008-03-05 2015-03-25 サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ アジュバント含有ワクチン組成物の安定化方法
AU2009223727B2 (en) * 2008-03-14 2014-09-11 Sanofi Pasteur Biologics, Llc Replication-defective flavivirus vaccines and vaccine vectors
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
EP2977457B1 (en) 2008-07-17 2021-09-01 Medigen, Inc. Idna vaccines and methods for using the same
US9198968B2 (en) * 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
BRPI0905645B8 (pt) 2009-10-27 2021-05-25 Fundacao Oswaldo Cruz vacina de dna contra o vírus da febre amarela
EP2731961A4 (en) 2011-07-12 2015-12-09 Us Government IDENTIFICATION OF A WEST NIL VIRUS CD4 T-CELL EPITOPS AND USE THEREOF
IN2014CN03925A (pt) * 2011-10-25 2015-07-03 Florida Gulf Coast University
GB201307528D0 (en) * 2013-04-26 2013-06-12 Univ Leuven Kath Bacterial artificial chromosomes
BR102016018430A2 (pt) * 2016-08-10 2018-02-27 Fundação Oswaldo Cruz Cassete de expressão heteróloga, constructo de dna e composição vacinal para imunizar contra flavivírus e/ou outros patógenos.
IL269534B2 (en) 2017-03-30 2025-01-01 Univ Queensland Chimeric molecules and their uses
EP4400174A3 (en) 2017-09-01 2024-10-23 The Francis Crick Institute Limited Immunoregulatory molecules and uses therefor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
CA2116980C (en) * 1991-09-19 2006-06-06 Ching-Juh Lai Chimeric and/or growth-restricted flaviviruses
US5736148A (en) * 1993-06-15 1998-04-07 The United States Of America As Represented By The Secretary Of The Army Infectious Japanese encephalitis virus cDNA clones that produce highly attenuated recombinant Japanese encephalitis virus, and vaccines thereof
GB9506782D0 (en) * 1995-04-01 1995-05-24 British Biotech Pharm Retroviral vectors
BRPI9701774B8 (pt) * 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
EP1034290A4 (en) * 1997-11-28 2004-09-15 Queensland Inst Med Res FLAVIVIRUS-SPECIFIC EXPRESSION AND DIFFUSION SYSTEM
WO2000015823A1 (en) * 1998-09-11 2000-03-23 Genvec, Inc. Alternatively targeted adenovirus

Also Published As

Publication number Publication date
GB0105877D0 (en) 2001-04-25
US20060159704A1 (en) 2006-07-20
AU2002235678B2 (en) 2007-10-18
EP1366170A1 (en) 2003-12-03
GB2372991B (en) 2004-11-17
WO2002072835A1 (en) 2002-09-19
ZA200209371B (en) 2004-02-18
AP2002002685A0 (en) 2002-12-31
CA2408214A1 (en) 2002-09-19
GB2372991A (en) 2002-09-11
OA12287A (en) 2006-05-12
US20030194801A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
BR0204470A (pt) Uso de flavivirus para a expressão de epitopos de proteìna e para o desenvolvimento de um novo virus vacinal vivo atenuado para imunização contra flavivirus e outros agentes infecciosos
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
MXPA04005364A (es) Clones de acido desoxirribonucleico infeccioso quimericos, circovirus de porcino quimericos y usos de los mismos.
CO5680456A2 (es) Composiciones de vacunas que comprenden lipooligosacaridos del inmunotipo l2 y/o l3 a partir de lgtb-neisseria minigitidis
AR036039A1 (es) Composicion de vacuna para el virus de la influenza
AR061894A1 (es) Vacunas para malaria
PE20140646A1 (es) Vacuna de virus de dengue inactivado
ECSP045300A (es) Antígenos virales
BR122019026154B8 (pt) vírus da dengue atenuado, composições farmacêuticas compreendendo dito vírus, kit, vacinas tetravalente, atenuada viva e inativada contra o vírus da dengue, e métodos para preparar um vírus da dengue e uma composição farmacêutica
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
HUP0102770A2 (hu) Sertésircovírus-antigént és sertésparvovírus-antigént tartalmazó vakcina
BR0111830A (pt) Método de produção de partìculas semelhantes ao vìrus da influenza (vlps), vlps da influenza, vlps quiméricas, proteìnas da influenza, composições imunogênica e farmacêutica, métodos de imunizar contra a infecção causada pelo vìrus da influenza ou por um microorganismo patogênico outro que não o vìrus da influenza, método de tratamento, e, célula hospedeira transfectada, infectada ou transformada com uma molécula de dna recombinante
DE60110822D1 (de) Zubereitung zur immunisierung gegen den aids-virus
BR0312474A (pt) Partìcula viral adjuvante
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
BR0312173A (pt) Mólecula de cdna, molécula e sequência de cdna recombinante, vetor, processo de preparação de partìculas de vìrus do sarampo infeccioso, composição imunogênica, composição de vacina e vìrus mononegaviral recombinante
PH12020551355A1 (en) Attenuated flaviviruses
MA32030B1 (fr) Vaccins anti-malaria
MX2018010958A (es) Vacuna para virus de zika atenuado vivo.
BRPI0419023A (pt) vacina contra poliomielite inativada e derivada do genero sabin de vìrus da polio
BR112022015313A2 (pt) Vacina de hpv
BR0207988A (pt) Cepas atenuadas vivas de vìrus de prrs
ZA202201571B (en) Polyvalent immunogenicity composition for human papillomavirus
EP1301208A4 (en) Vaccine
ATE479440T1 (de) Virusstämme und zusammensetzungen des prrs- syndroms (porcine reproductive und respiratory syndrome) von schweinen

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: PARA QUE SEJA ACEITA A PETICAO DE NO 039395 DE 09/07/2006 REFERENTE AO DESARQUIVAMENTO DO PEDIDO, SOLICITA-SE A APRESENTACAO DE PETICAO REFERENTE AO EXAME TECNICO.

B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO NO 020060187188/RJ DE 19/12/2006, EM VIRTUDE DO DISPOSTO NO ART 219 2 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15V Prolongation of time limit allowed

Free format text: RECONHECIDO O OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 32 DIAS PARA CUMPRIMENTO DE EXIGENCIA, NOS TERMOS DO ARTIGO 221 PARAGRAFO 2O DA LPI E DA RESOLUCAO 116/04.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]